Table 2.
Characteristics of identified randomised trials of glucosamine or chondroitin for osteoarthritis of hip or knee by treatment arm
| Trial | Treatment (daily dose) | Patients randomised | Patients analysed for pain | Patients analysed for joint space |
|---|---|---|---|---|
| Glucosamine v placebo | ||||
| Noack 199433 | Glucosamine sulphate (1500 mg)/placebo | 126/126 | 120/121 | NA |
| Reginster 200134 | Glucosamine sulphate (1500 mg)/placebo | 106/106 | 106/106 | 106/106 |
| Pavelka 200235 | Glucosamine sulphate (1500 mg)/placebo | 101/101 | 101/101 | 101/101 |
| McAlindon 200436 | Glucosamine sulphate (1500 mg) or glucosamine hydrochloride (1500 mg)/placebo | 101/104 | 101/104 | NA |
| Herrero-Beaumont 200739 | Glucosamine (1500 mg)/placebo | 109/107 | 106/104 | NA |
| Rozendaal 200841 | Glucosamine (1500 mg)/placebo | 111/111 | 111/111 | 111/111 |
| Chondroitin v placebo | ||||
| Michel 200537 | Chondroitin sulphate (800 mg)/placebo | 150/150 | 150/150 | 150/150 |
| Mazières 200738 | Chondroitin sulphate (1000 mg)/placebo | NA | 153/154 | NA |
| Kahan 200943 | Chondroitin sulphate (800 mg)/placebo | 309/313 | 309/313 | 309/313 |
| Glucosamine v chondroitin v glucosamine and chondroitin combined v placebo | ||||
| Clegg 200613 | Glucosamine hydrochloride (1500 mg)/chondroitin sulphate (1200 mg)/glucosamine hydrochloride (1500 mg) and chondroitin sulphate (1200 mg)/placebo | 317/318/317/313 | 317/318/317/313 | 77/71/59/70 |
NA=not available.